Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIL62 Plus Lenalidomide in R/R FL and MZL
NCT04110301Phase 2Recruiting
- Sponsor
- Beijing Tianguangshi Pharmaceutical Technology
- Start
- Nov 2019
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Bejescin in follicular lymphoma (FL) and marginal zone lymphoma (MZL), sponsored by Beijing Tianguangshi Pharmaceutical Technology. Primary endpoint: Percentage of Participants With an Objective Response of Complete Response. Started Nov 2019; status: recruiting.
02
Drugs
Bejescin
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04110301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04110301.